Effect of Liraglutide combined with Metformin on type 2 diabetes mellitus patients with coronary heart disease
LIANG Huibin1 HAN Yi2
1.Department of Anesthesiology, Shanxi Medical University, Shanxi Province, Taiyuan 030000, China;
2.Department of Anesthesiology, the Second Hospital of Shanxi Medical University, Shanxi Province, Taiyuan 030001, China
Abstract：Objective To observe the effect of Liraglutide combined with Metformin on patients with type 2 diabetes mellitus (T2DM) complicated with coronary heart disease. Methods The clinical data of 80 patients with type 2 diabetes mellitus and coronary heart disease admitted to the Department of Endocrinology of the Second Hospital of Shanxi Medical University from January to August 2021 were prospectively analyzed. According to the random number table method, they were divided into observation group and control group, with 40 cases in each group. The observation group was given Liraglutide and Metformin on the basis of the basic treatment of coronary heart disease, while the control group was given Metformin on the basis of the basic treatment of coronary heart disease. The changes in clinical efficacy, blood glucose, blood lipids, cardiac ultrasound, body mass index (BMI), nociceptin/orphanin FQ peptide (N/OFQ), and lipoprotein-associated phospholipase A2 (Lp-PLA2) before and after treatment were compared between the two groups. Results The clinical efficacy of the observation group was better than that of the control group, and the difference was statistically significant (P ＜ 0.05). After treatment, the fasting plasma glucose (FPG), 2 h postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (LDL-C), left ventricular end-diastolic diameter (LVEDD), BMI, N/OFQ, and Lp-PLA2 levels were lower than those before treatment, while high density lipoprotein cholesterol (HDL-C), left ventricular ejection fraction (LVEF), maximum peak velocity of early diastolic / maximum peak velocity of late diastolic (E/A) levels of the two groups were higher than those before treatment, and the differences were statistically significant (P ＜ 0.05). After treatment, the indexes of TG, TC, LDL-C, LVEDD, BMI, N/OFQ, and Lp-PLA2 in the observation group were lower than those in the control group, while the indexes of HDL-C, LVEF, and E/A were higher than those in the control group, and the differences were statistically significant (P ＜ 0.05). Conclusion Liraglutide combined with metformin can effectively regulate blood sugar, blood lipids, cardiac function, BMI, N/OFQ, and Lp-PLA2. The effect is better than Metformin alone, with fewer adverse reactions.
[1] 汤爽，张丹，韩霜，等.丹红注射液治疗糖尿病合并冠心病的Meta分析[J].中国中药杂志，2021，46（1）：237-246.
[2] Sheahan KH，Wahlberg EA，Gilbert MP. An overview of GLP-1 agonists and recent cardiovascular outcomes trials [J]. Postgrad Med J，2020，96（1133）：156-161.
[3] Reed J，Bain S，Kanamarlapudi V. Recent advances in understanding the role of glucagon-like peptide 1 [J]. F1000Res，2020，9：F1000 Faculty Rev-239.
[4] Patsouras A，Farmaki P，Garmpi A，et al. Screening and Risk Assessment of Coronary Artery Disease in Patients With Type 2 Diabetes：An Updated Review [J]. In Vivo，2019，33（4）：1039-1049.
[5] Guo Z，Yao TP，Wang JP，et al. Acute myocardial ischemia up-regulates nociceptin/orphanin FQ in dorsal root ganglion and spinal cord of rats [J]. Neurosci Lett，2008，433（3）：274-278.
[6] 解梦莉，苏敬，李静，等.糖尿病无症状性心肌缺血患者血清孤啡肽与脂蛋白相关磷脂酶A2水平变化的研究[J].天津医药，2021，49（4）：390-395.
[7] Kiluk P，Baran A，■widerska M，et al. Lp-PLA2 as a promising predictor of comorbidities in patients with severe psoriasis [J]. J Dermatolog Treat，2020，31（5）：524-530.
[8] 中华医学会心血管病学分会流行病学组，中国医师协会心血管内科医师分会，中国老年学学会心脑血管病专业委员会.糖代谢异常与动脉粥样硬化性心血管疾病临床诊断和治疗指南[J].中华心血管病杂志，2015，43（6）：488-506.
[9] 中华医学会内分泌学分会.中国成人2型糖尿病患者动脉粥样硬化性脑心血管疾病分级预防指南[J].中华内分泌代谢杂志，2016，32（7）：540-545.
[10] Hussein AM，Eid EA，Taha M，et al. Comparative Study of the Effects of GLP1 Analog and SGLT2 Inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats：Possible Underlying Mechanisms [J]. Biomedicines，2020，8（3）：43.
[11] Donica CL，Ramirez VI，Awwad HO，et al. Orphanin FQ/nociceptin activates nuclear factor kappa B [J]. J Neuroimmune Pharmacol，2011，6（4）：617-625.
[12] 解梦莉，韩毅，赵晓英，等.围术期糖尿病患者血清孤啡肽含量的变化[J].麻醉安全与质控，2020，4（5）：273-277.
[13] Fontana F，Bernardi P，Pizzi C，et al. Plasma nociceptin/orphanin FQ levels rise after spontaneous episodes of angina，but not during induced myocardial ischemia [J]. Peptides，2009，30（9）：1705-1709.
[14] Zingale GA，Bellia F，Ahmed IMM，et al. IDE Degrades Nociceptin/Orphanin FQ through an Insulin Regulated Mechanism [J]. Int J Mol Sci，2019，20（18）：44-47.
[15] Wiciński M，Szadujkis-Szadurska K，W?誰clewicz MM，et al. The role of Rho-kinase and calcium ions in constriction triggered by ET-1 [J]. Microvasc Res，2018，119：84-90.
[16] An JH，Chen ZY，Ma QL，et al. Liraglutide improves atherosclerosis by regulating long non-coding RNA RMRP/miR-128-1-5P/Gadd45g axis [J]. Eur Rev Med Pharmacol Sci，2020，24（5）：2725-2737.
[17] Bai XJ，Hao JT，Zheng RH，et al. Glucagon-Like Peptide-1 Analog Liraglutide Attenuates Pressure-Overload Induced Cardiac Hypertrophy and Apoptosis through Activating ATP Sensitive Potassium Channels [J]. Cardiovasc Drugs Ther，2021，35（1）：87-101.
[18] 员婷.磷酸西格列汀联合二甲双胍对2型糖尿病患者血糖控制及胰岛素抵抗的治疗效果[J].中国医药导报，2021，18（6）：91-94.
[19] 侯丽萍，赵红玲，张雪坤.米格列醇和阿卡波糖分别联合二甲双胍对老年2型糖尿病患者疗效对比[J].中国老年学杂志，2017，37（1）：207-208.
[20] Li SN，Wang X，Zeng QT，et al. Metformin inhibits nuclear factor kappaB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits [J]. Heart Vessels，2009，24（6）：446-453.
[21] 王明尉.利拉鲁肽联合二甲双胍治疗2型糖尿病的临床效果[J].中国当代医药，2021，28（34）：131-134.
[22] 翟小趣，李启亮.二甲双胍联合利拉鲁肽对糖尿病患者糖脂代谢、胰岛素抵抗及血清炎症因子的影响[J].中国医药科学，2020，10（3）：77-80.
[23] 孙娜，李雪璐.利拉鲁肽注射液联合二甲双胍片治疗2型糖尿病伴肥胖患者的临床研究[J].中国临床药理学杂志，2020，36（11）：1453-1456.
[24] 董非斐，吉晓理，符薇薇，等.利拉鲁肽注射液联合二甲双胍片治疗2型糖尿病伴冠心病的临床研究[J].中国临床药理学杂志，2018，34（17）：2077-2079.
[25] 张继东，荣朝，胡娟，等.地特胰岛素联合利拉鲁肽对二甲双胍无效的老年2型糖尿病的疗效[J].中国医药导报，2020，17（21）：74-77.
[26] 由晓丹.利拉鲁肽联合二甲双胍对超重或肥胖2型糖尿病患者心血管、胰岛β细胞功能及炎症因子水平影响[J].中国医学创新，2022，19（8）：10-14.
[27] Takihata M，Terauchi Y. The efficacy and safety of luseo-gliflozin and sitagliptin depending on the sequence of administration in patients with type 2 diabetes mellitus：a randomized controlled pilot study [J]. Expert Opin Pharmacother，2019，20（17）：2185-2194.
[28] Santilli F，Simeone PG，Guagnano MT，et al. Effects of Liraglutide on Weight Loss，Fat Distribution，and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes [J]. Diabetes Care，2017，40（11）：1556-1564.
[29] 卓巍.利拉鲁肽联合二甲双胍治疗2型糖尿病的临床效果及安全性分析[J].中外医学研究，2021，19（29）：135-137.
[30] 季欢欢，霍本念，张妮，等.基于比值失衡法对利拉鲁肽上市后安全信号的检测与评价[J].医药导报，2022，41（1）：48-53.
京公网安备 11010502046598号